All Stories

  1. Evaluating Cefepime Dosing Strategies in Pseudomonas aeruginosa Bacteremia: A Retrospective Cohort Analysis
  2. Cost analysis of urine testing for hospitalized patients in the emergency department
  3. Impact of Extracorporeal Membrane Oxygenation (ECMO) on Serum Concentrations of Cefepime
  4. Impact of Extra-Corporeal Membrane Oxygenation (ECMO) on Serum Concentrations of Cefepime
  5. Assessment of the impact of centralized bioMérieux BACT/ALERT® VIRTUO® blood culture system (VIRTUO) implementation on outcomes in patients with gram-negative bacteremia
  6. A comparison of clinical outcomes associated with dosing metronidazole every 8 hours versus every 12 hours: a systematic review and metaanalysis
  7. Diagnosis and Outcomes of Fungal Co-Infections in COVID-19 Infections: A Retrospective Study
  8. Doxycycline Induced Pancreatitis: An Uncommon Complication of a Common Drug
  9. COVID-19 Mortality and Therapeutics in Nebraska and Southwest Iowa during Early Pandemic
  10. Targeted Immuno-Antiretroviral to Promote Dual Protection against HIV: A Proof-of-Concept Study
  11. Improving understanding and utilization of the antibiogram among medical residents
  12. Beta-Lactam vs. Fluoroquinolone Monotherapy for Pseudomonas aeruginosa Infection: A Systematic Review and Meta-Analysis
  13. Bamlanivimab use in mild‐to‐moderate COVID‐19 disease: A matched cohort design
  14. A Concept Evaluation Study of a New Combination Bictegravir plus Tenofovir Alafenamide Nanoformulation with Prolonged Sustained-Drug-Release Potency for HIV-1 Preexposure Prophylaxis
  15. Targeted Immuno-Antiretroviral HIV Therapeutic Approach to Provide Dual Protection and Boosts Cellular Immunity: A Proof-of-Concept Study
  16. Targeted immuno-antiretroviral HIV therapeutic approach to provide dual protection and boosts cellular immunity: A proof-of-concept study
  17. Implementation of a Health-System Wide Antimicrobial Stewardship Program in Omaha, NE
  18. Corrigendum to “Nanoencapsulation introduces long-acting phenomenon to tenofovir alafenamide and emtricitabine drug combination: A comparative pre-exposure prophylaxis efficacy study against HIV-1 vaginal transmission” [Journal of Controlled Release 29...
  19. Effect of antimicrobial stewardship with rapid MALDI-TOF identification and Vitek 2 antimicrobial susceptibility testing on hospitalization outcome
  20. Correction to: Pharmacokinetic and Tissue Distribution Profile of Long Acting Tenofovir Alafenamide and Elvitegravir Loaded Nanoparticles in Humanized Mice Model
  21. A potential long-acting bictegravir loaded nano-drug delivery system for HIV-1 infection: A proof-of-concept study
  22. Effect of Antimicrobial Stewardship with Rapid MALDI-TOF Identification and Vitek 2 Antimicrobial Susceptibility Testing on Hospitalization Outcome
  23. A review of CCR5 antibodies against HIV: current and future aspects
  24. Indole-2-Carboxamides Are Active against Mycobacterium abscessus in a Mouse Model of Acute Infection
  25. Nanoencapsulation introduces long-acting phenomenon to tenofovir alafenamide and emtricitabine drug combination: A comparative pre-exposure prophylaxis efficacy study against HIV-1 vaginal transmission
  26. Ceftaroline fosamil for the treatment of Gram-positive endocarditis: CAPTURE study experience
  27. Development and validation of LC-MS/MS method for quantification of bictegravir in human plasma and its application to an intracellular uptake study
  28. Long-acting parenteral combination antiretroviral loaded nano-drug delivery system to treat chronic HIV-1 infection: A humanized mouse model study
  29. LC-MS/MS method for the simultaneous determination of tenofovir, emtricitabine, elvitegravir and rilpivirine in dried blood spots
  30. Discovery of a non-nucleoside RNA polymerase inhibitor for blocking Zika virus replication through in silico screening
  31. Review of NRTIs
  32. Pharmacokinetic and Tissue Distribution Profile of Long Acting Tenofovir Alafenamide and Elvitegravir Loaded Nanoparticles in Humanized Mice Model
  33. Cellulose Acetate Phthalate and Antiretroviral Nanoparticle Fabrications for HIV Pre-Exposure Prophylaxis
  34. Evaluation of Staphylococcus aureus Bacteremia: Academic and Community-Based Management Within the Same Health System
  35. Tenofovir alafenamide and elvitegravir loaded nanoparticles for long-acting prevention of HIV-1 vaginal transmission
  36. Nanoformulation of emtricitabine for HIV
  37. Brief review of HIV cure strategies.
  38. Education and Communication in an Interprofessional Antimicrobial Stewardship Program
  39. LC-MS/MS quantification of NRTI, NNRTI, and INSTI in mice
  40. topical TDF NP
  41. Early versus late surgical intervention or medical management for infective endocarditis: a systematic review and meta-analysis
  42. Natural polyphenols: potential in the prevention of sexually transmitted viral infections
  43. Correction: Nanoformulations of Rilpivirine for Topical Pericoital and Systemic Coitus-Independent Administration Efficiently Prevent HIV Transmission
  44. Nanoformulations of Rilpivirine for Topical Pericoital and Systemic Coitus-Independent Administration Efficiently Prevent HIV Transmission
  45. Confocal fluorescence microscopy: An ultra-sensitive tool used to evaluate intracellular antiretroviral nano-drug delivery in HeLa cells
  46. Early Initiation of Antiretroviral Therapy Can Functionally Control Productive HIV-1 Infection in Humanized-BLT Mice
  47. Direct Differentiation of Adult Ocular Progenitors into Striatal Dopaminergic Neurons
  48. Thermosensitive Gel Containing Cellulose Acetate Phthalate-Efavirenz Combination Nanoparticles for Prevention of HIV-1 Infection
  49. Hepatitis C therapy: Looking toward interferon-sparing regimens
  50. Review of treatments for hepatitis C.
  51. Assessing Appropriateness of Antimicrobial Therapy: In the Eye of the Interpreter
  52. Breaking Down the Barriers: Challenges With Development and Implementation of an Industry-Sponsored Antimicrobial Stewardship Data Collection and Analysis Tool
  53. Development and validation of a simple and isocratic reversed-phase HPLC method for the determination of rilpivirine from tablets, nanoparticles and HeLa cell lysates
  54. Aminoglycoside-Induced Nephrotoxicity—A Focus on Monitoring
  55. Antimicrobial Treatment of Asymptomatic Bacteriuria in Noncatheterized Adults: A Systematic Review
  56. A review of nanotechnological approaches for the prophylaxis of HIV/AIDS
  57. Polymeric Nanoparticles Containing Combination Antiretroviral Drugs for HIV Type 1 Treatment
  58. Does Antibiotic De-escalation for Nosocomial Pneumonia Impact Intensive Care Unit Length of Stay?
  59. Development and evaluation of a thermosensitive vaginal gel containing raltegravir+efavirenz loaded nanoparticles for HIV prophylaxis
  60. Lopinavir/Ritonavir: A Review for 2011
  61. Letter in Response to the Infectious Diseases Society of America’s 10 × ‘20 Initiative
  62. A Survey of Pharmacy Students' Experiences With Gambling
  63. Teaching Heart Failure Treatment Guidelines and Assessing Heart Failure Therapy
  64. Research Spotlight: Antiretroviral nanoparticles: an extended drug delivery modality
  65. Antiretroviral release from poly(DL-lactide-co-glycolide) nanoparticles in mice
  66. Combination antiretroviral drugs in PLGA nanoparticle for HIV-1
  67. Rotation Students' Perceptions of Clinical Workload Documentation Using a Personal Digital Assistant
  68. Impact of Pharmacist Intervention on Diabetes Patients in an Ambulatory Setting
  69. Nurse Satisfaction Using Insulin Pens in Hospitalized Patients
  70. Macrophage Delivery of Nanoformulated Antiretroviral Drug to the Brain in a Murine Model of NeuroAIDS
  71. Role of Prostanoid Production and Receptors in the Regulation of Retinal Endogenous Amino Acid Neurotransmitters by 8-Isoprostaglandin E2, Ex Vivo
  72. Brain as an HIV sequestered site
  73. Nursing Satisfaction Survey
  74. National Survey of Volunteer Pharmacy Preceptors
  75. Patient satisfaction and costs associated with insulin administered by pen device or syringe during hospitalization
  76. A randomized trial of the peri-operative use of COX-2 inhibitors in Lichtenstein herniorrhaphy
  77. ANTIMICROBIAL PHARMACODYNAMICS IN THEORY AND CLINICAL PRACTICE, 2ND EDITION
  78. Regulation of retinal morphology and posterior segment amino acids by 8-isoprostaglandin E2 in bovine eyes ex vivo
  79. EFFICACY OF ANTIMICROBIALS FOR ACUTE EXACERBATION OF CHRONIC BRONCHITIS EPISODES
  80. Preprinted risk assessment and prophylaxis order form for venous thromboembolism
  81. Laboratory investigations for the morphologic, pharmacokinetic, and anti-retroviral properties of indinavir nanoparticles in human monocyte-derived macrophages
  82. Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery
  83. Quantitative magnetic resonance and SPECT imaging for macrophage tissue migration and nanoformulated drug delivery
  84. Nanotechnology: A Focus on Nanoparticles as a Drug Delivery System
  85. Neuroimaging and Proteomic Tracking of Neurodegeneration in MPTP-Treated Mice
  86. Quantitative 1H Magnetic Resonance Spectroscopic Imaging Determines Therapeutic Immunization Efficacy in an Animal Model of Parkinson's Disease
  87. Proteomic fingerprints distinguish microglia, bone marrow, and spleen macrophage populations
  88. Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease
  89. Proteomic fingerprinting of HIV-1-infected human monocyte-derived macrophages: a preliminary report
  90. Comparison of Gemfibrozil and Fenofibrate in Patients with Dyslipidemic Coronary Heart Disease
  91. Maximizing Outcomes in Respiratory Tract Infections in the Age of Resistance
  92. Optimizing Economic Outcomes in Acute Exacerbations of Chronic Bronchitis
  93. Antibacterials and Acute Exacerbation of Chronic Bronchitis
  94. Potential Influence of Timing of Low-Density Lipoprotein Cholesterol Evaluation in Patients with Acute Coronary Syndrome
  95. Individualized Pharmacokinetic Monitoring Results in Less Aminoglycoside-Associated Nephrotoxicity and Fewer Associated Costs
  96. Diagnosis and Treatment of Complicated Tubercular Meningitis
  97. Simple liquid chromatographic method for the analysis of the blood brain barrier permeability characteristics of ceftriaxone in an experimental rabbit meningitis model
  98. Pharmacodynamics and pharmacokinetics of A-80556 using microdialysis in a Streptococcus pneumoniae meningitis model
  99. Notes on Medical Bacteriology. 4Th Edition
  100. Cost Considerations in Therapeutic Drug Monitoring of Aminoglycosides
  101. Use of Therapeutic Drug Monitoring in Pharmacoeconomics
  102. Economic Aspects of Pharmacokinetic Services
  103. Effect of Seven Fluoroquinolones on the Determination of Serum Creatinine by the Picric Acid and Enzymatic Methods
  104. Omeprazole: A Comprehensive Review
  105. Aminoglycoside Forecasting in Neutropenic Patients with Cancer
  106. Impact of Food on the Bioavailability of Encainide
  107. Predictive Performance of Bayesian and Nonlinear Least-Squares Regression Programs for Lidocaine
  108. Efficacy and safety of early versus late initiation of warfarin during heparin therapy in acute thromboembolism
  109. Influence of Mexiletine on the Pharmacokinetics of Theophylline in Healthy Volunteers
  110. Impact of a Clinical Pharmacokinetic Service on Patients Treated with Aminoglycosides
  111. Does Accepting Pharmacokinetic Recommendations Impact Hospitalization? A Cost-Benefit Analysis
  112. Retrospective comparison of pharmacokinetic service and no service on patient outcomes
  113. Case report and literature review